Monte Rosa Therapeutics Initiates Phase 1 Study of NEK7-Directed Molecular Glue Degrader MRT-8102 for Inflammatory Diseases

Reuters

08/07

<a href="https://laohu8.com/S/GLUE">Monte Rosa Therapeutics</a> Initiates Phase 1 Study of NEK7-Directed Molecular Glue Degrader MRT-8102 for Inflammatory Diseases

Monte Rosa Therapeutics Inc., a clinical-stage biotechnology company, has announced the commencement of a Phase 1 study for its NEK7-directed molecular glue degrader, MRT-8102. This study aims to explore a novel therapeutic approach for treating inflammatory diseases driven by the NLRP3 inflammasome. Initial results from this study are anticipated in the first half of 2026. Additionally, Monte Rosa is advancing its VAV1-directed MGD, MRT-6160, towards the initiation of multiple Phase 2 studies in immune-mediated diseases, in collaboration with Novartis. The company also continues its Phase 1/2 study of GSPT1-directed MGD MRT-2359 in heavily pretreated, castration-resistant prostate cancer patients, with further results expected in the second half of 2025. Monte Rosa maintains a strong financial position to support operations into 2028, through multiple anticipated proof-of-concept clinical readouts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9507677-en) on August 07, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2557557157"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557557157\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557557157?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-07 19:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557557157","market":"nz","top_or_hot":-1,"title":"Monte Rosa Therapeutics Initiates Phase 1 Study of NEK7-Directed Molecular Glue Degrader MRT-8102 for Inflammatory Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GLUE\">Monte Rosa Therapeutics</a> Initiates Phase 1 Study of NEK7-Directed Molecular Glue Degrader MRT-8102 for Inflammatory Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Monte Rosa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc., a clinical-stage biotechnology company, has announced the commencement of a Phase 1 study for its NEK7-directed molecular glue degrader, MRT-8102. This study aims to explore a novel therapeutic approach for treating inflammatory diseases driven by the NLRP3 inflammasome. Initial results from this study are anticipated in the first half of 2026. Additionally, Monte Rosa is advancing its VAV1-directed MGD, MRT-6160, towards the initiation of multiple Phase 2 studies in immune-mediated diseases, in collaboration with Novartis. The company also continues its Phase 1/2 study of GSPT1-directed MGD MRT-2359 in heavily pretreated, castration-resistant prostate cancer patients, with further results expected in the second half of 2025. Monte Rosa maintains a strong financial position to support operations into 2028, through multiple anticipated proof-of-concept clinical readouts.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9507677-en) on August 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Monte Rosa Therapeutics Initiates Phase 1 Study of NEK7-Directed Molecular Glue Degrader MRT-8102 for Inflammatory Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMonte Rosa Therapeutics Initiates Phase 1 Study of NEK7-Directed Molecular Glue Degrader MRT-8102 for Inflammatory Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-07 19:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GLUE\">Monte Rosa Therapeutics</a> Initiates Phase 1 Study of NEK7-Directed Molecular Glue Degrader MRT-8102 for Inflammatory Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Monte Rosa <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc., a clinical-stage biotechnology company, has announced the commencement of a Phase 1 study for its NEK7-directed molecular glue degrader, MRT-8102. This study aims to explore a novel therapeutic approach for treating inflammatory diseases driven by the NLRP3 inflammasome. Initial results from this study are anticipated in the first half of 2026. Additionally, Monte Rosa is advancing its VAV1-directed MGD, MRT-6160, towards the initiation of multiple Phase 2 studies in immune-mediated diseases, in collaboration with Novartis. The company also continues its Phase 1/2 study of GSPT1-directed MGD MRT-2359 in heavily pretreated, castration-resistant prostate cancer patients, with further results expected in the second half of 2025. Monte Rosa maintains a strong financial position to support operations into 2028, through multiple anticipated proof-of-concept clinical readouts.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9507677-en) on August 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3QW5Z07.USD","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nNDL2XY0Gc:1","article_id":"2557557157","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557557157","pubTimestamp":1754564611,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Monte Rosa Therapeutics Inc., a clinical-stage biotechnology company, has announced the commencement of a Phase 1 study for its NEK7-directed molecular glue degrader, MRT-8102. This study aims to explore a novel therapeutic approach for treating inflammatory diseases driven by the NLRP3 inflammasome. Initial results from this study are anticipated in the first half of 2026. Additionally, Monte Rosa is advancing its VAV1-directed MGD, MRT-6160, towards the initiation of multiple Phase 2 studies in immune-mediated diseases, in collaboration with Novartis. The company also continues its Phase 1/2 study of GSPT1-directed MGD MRT-2359 in heavily pretreated, castration-resistant prostate cancer patients, with further results expected in the second half of 2025. Monte Rosa maintains a strong financial position to support operations into 2028, through multiple anticipated proof-of-concept clinical readouts.Disclaimer: This news brief was created by Public Technologies  using generative artific","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4139":"生物科技","BK4585":"ETF&股票定投概念","GLUE":"Monte Rosa Therapeutics","BK4112":"金融交易所和数据","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4539":"次新股"},"translate_title":"Monte Rosa Therapeutics启动NEK7定向分子胶降解剂MRT-8102治疗炎症性疾病的1期研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLUE":0.9,"NDAQ":0.9},"content_text":"Monte Rosa Therapeutics Initiates Phase 1 Study of NEK7-Directed Molecular Glue Degrader MRT-8102 for Inflammatory Diseases\n    \n\n        Monte Rosa Therapeutics Inc., a clinical-stage biotechnology company, has announced the commencement of a Phase 1 study for its NEK7-directed molecular glue degrader, MRT-8102. This study aims to explore a novel therapeutic approach for treating inflammatory diseases driven by the NLRP3 inflammasome. Initial results from this study are anticipated in the first half of 2026. Additionally, Monte Rosa is advancing its VAV1-directed MGD, MRT-6160, towards the initiation of multiple Phase 2 studies in immune-mediated diseases, in collaboration with Novartis. The company also continues its Phase 1/2 study of GSPT1-directed MGD MRT-2359 in heavily pretreated, castration-resistant prostate cancer patients, with further results expected in the second half of 2025. Monte Rosa maintains a strong financial position to support operations into 2028, through multiple anticipated proof-of-concept clinical readouts.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9507677-en) on August 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}